Microb Drug Resist. 2000 Summer;6(2):133-41.
Epidemiological study of staphylococcal colonization and cross-infection in two West African Hospitals.

Aires De Sousa M, Santos Sanches I, Ferro ML, De Lencastre H.

Unidade de Genetica Molecular, Instituto de Tecnologia Quimica e Biologica da Universidade Nova de Lisboa, Oeiras, Portugal.

Surveillance in two medium-size (250-300 beds) hospitals located in the most populated islands of Cape Verde was undertaken in July 1997 in order to obtain data concerning nasal carriage of staphylococci. Nasal swabs (172) taken from inpatients and health care workers (HCW) from different internment services yielded 68 Staphylococcus aureus and 105 coagulase-negative staphylococcal (CNS) isolates, demonstrating extensive colonization of both inpatients and HCW by S. aureus (carriage rate 41%) and CNS (carriage rate 65%). The most frequent CNS species were S. epidermidis and S. haemolyticus. Three species--S. aureus, S. epidermidis, and S. sciuri-were recovered from wound swabs. The antibiotic susceptibility profiles of S. aureus and CNS differed sharply: all 68 S. aureus were resistant to penicillin but were fully susceptible to oxacillin as well as the other antimicrobial agents tested-gentamicin; erythromycin, except for three strains; ciprofloxacin; sulfamethoxazole-trimethoprim, except for two strains; vancomycin; and amoxicillin/clavulanate. In contrast, most (91/105) of CNS were resistant to both penicillin and oxacillin, and a variable but substantial proportion of CNS isolates also carried multiresistant traits to gentamicin, erythromycin, sulfamethoxazole-trimethoprim, and amoxicillin/clavulanate. The analysis by PFGE of the methicillin-susceptible S. aureus (MSSA) and the methicillin-resistant S. epidermidis (MRSE) strains provided evidence for extensive cross-infection and cross-colonization from HCW to patients.

Source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10990268&dopt=Abstract antibiotic amoxicillin




Drugs. 2001;61(6):815-29; discussion 830-1.
Telithromycin.

Balfour JA, Figgitt DP.

Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Telithromycin is the first member of a new family of the macrolide-lincosamide-streptogramin-B (MLS(B)) class of antimicrobials, the ketolides. It has a good spectrum of activity against respiratory pathogens, including penicillin- and erythromycin-resistant pneumococci, as well as intracellular and atypical bacteria. Furthermore, it has a low potential to select for resistance or induce cross-resistance among other MLS(B) antimicrobials. At the recommended dosage of 800 mg orally once daily, telithromycin reaches maximal plasma concentrations of about 2 mg/L. It penetrates rapidly into bronchopulmonary, tonsillar, sinus and middle ear tissues and/or fluids and achieves high concentrations at sites of infection. It also concentrates within polymorphonuclear neutrophils. In clinical trials in patients with community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) or pharyngitis/tonsillitis caused by group A beta-haemolytic streptococci, telithromycin 800 mg once daily achieved clinical cure rates of 86 to 95%. In acute maxillary sinusitis (AMS), cure rates were 73 to 91%. A 7- to 10-day regimen of telithromycin was as effective as a 10-day course of amoxicillin 1000 mg 3 times daily, clarithromycin 500 mg twice daily or a 7- to 10-day course of trovafloxacin 200 mg once daily for treating CAP. A 5-day regimen of telithromycin was as effective as a 10-day regimen of cefuroxime axetil 500 mg twice daily or amoxicillin/clavulanic acid 500/125 mg 3 times daily in AECB. A 5-day regimen of telithromycin was as effective as a 10-day regimen of clarithromycin 250 mg twice daily or phenoxymethylpenicillin 500 mg 3 times daily in pharyngitis/tonsillitis, or a 10-day regimen of amoxicillin/clavulanic acid 500/125 mg 3 times daily in patients with AMS. Telithromycin was well tolerated across all patient populations. Adverse events associated with telithromycin were generally mild to moderate in intensity and seldom led to treatment discontinuation. The most frequent adverse events were diarrhoea (13.3%) and nausea (8.1%). Other adverse events included dizziness and vomiting.

Source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11398913&dopt=Abstract antibiotic amoxicillin




Chemotherapy. 2001 May-Jun;47(3):215-8.
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species.

Maraki S, Mouzas IA, Kontoyiannis DP, Chatzinikolaou I, Tselentis Y, Samonis G.

Division of Medicine, University of Crete, Heraklion, Crete, Greece.

BACKGROUND: Amoxicillin and clarithromycin have been used extensively for the eradication of Helicobacter pylori. However, no study has examined the impact of their combination on the Candida albicans concentration of the gastrointestinal (GI) tract. This is the first study examining and comparing directly the effect of amoxicillin, clarithromycin and their combination on the C. albicans concentration of the human GI tract. METHODS: Thirty-three adult patients (11 in each antibiotic group) were studied prospectively. Quantitative stool cultures for Candida were conducted at the beginning, the end and 1 week after the discontinuation of antibiotic treatment. RESULTS: All three regimens increased the GI colonization in patients by Candida. The combination of amoxicillin with clarithromycin caused the highest increase; however, this was not statistically significant. CONCLUSION: Amoxicillin and clarithromycin used either alone or in combination cause a small to moderate increase in GI colonization by Candida. Hence, these drugs could be safely used in patients at risk for candidiasis originating from the GI tract. Copyright 2001 S. Karger AG, Basel

Source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11306791&dopt=Abstract antibiotic amoxicillin




Pediatr Dermatol. 2000 Sep-Oct;17(5):360-3.
The effects of amoxicillin therapy on skin flora in infants.

Brook I.

Department of Pediatrics, Georgetown University School of Medicine, Washington, DC, USA.

In order to determine the effect of amoxicillin therapy on the perineal skin microbial flora in infants, we took quantitative bacterial and fungal cultures of perineal and sternal areas from 25 infants treated with amoxicillin (40 mg/kg/day) for 10 days. Specimens were obtained prior to therapy, within 3 days of conclusion of therapy, and 14-16 days later. Immediately following therapy, a decline in the number of bacterial isolates occurred on both the perineum (89 to 47) and sternum (84 to 39). The greatest decline occurred in the number of anaerobic bacteria (mostly Peptostreptococcus spp. and Propionibacterium acnes). Other organisms that were less often isolated were aerobic streptococci and Staphylococcus epidermidis. The number of Candida albicans isolates increased from 3 to 11 (p < 0.05) on the perineum, and 1 to 7 (p < 0.025) on the sternum. Four of the infants developed diaper dermatitis. The density of C. albicans increased more than 14-fold following amoxicillin therapy. Cultures done 14-16 days after cessation of therapy revealed an increase in the number of bacterial isolates on the perineum (47 to 72) and on the sternum (39 to 61) and a decline in recovery of C. albicans. This study demonstrates the effects of amoxicillin on the ecology of skin microbial flora in infants-a decrease in the number of bacterial isolates and an increase in recovery of C. albicans.

Source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11085662&dopt=Abstract antibiotic amoxicillin